Haemonetics (HAE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.35
- Estimate
- $1.29
- Surprise
- +4.6%
- Revenue (period 2026-09-26)
- $357.8M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
Haemonetics (HAE) beat the $1.29 estimate with adjusted EPS of $1.35 — a clear 4.6% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HAE Sell at 5.0/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +4.6% surprise compares with a +4.1% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: apheresis equipment from Asia
- Concentration risk — Supplier: Tetakawi
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $118.96
- Stop
- $112.03
The stock trades at 54.9× trailing but 21.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
HAE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $5.65B
- P/E (fwd)
- 21.5
- P/E (ttm)
- 54.9
- 52-week range
- $51.00–$132.00
- Off 52-week high
- 9.9%
- RSI (14)
- 50
- Volume vs avg
- 0.29×
- Score today
- 5.0/10